41 results
6-K
EX-99.1
PRE
Prenetics Global Limited - Ordinary Shares
1 Apr 24
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results
7:38am
Direct costs
Gross profit
Other income and other net gain
Selling and distribution expenses5
Research and development expenses5
Impairment loss … 31,
Year Ended
December 31,
(Restated)
Direct costs
Selling and distribution expenses
Research and development expenses
Administrative and other
424B3
PRE
Prenetics Global Limited - Ordinary Shares
16 Feb 24
Prospectus supplement
6:13am
believe that we have a strong capability and a proven track record in research and development, transforming technologies into commercial products … technologies, devote greater resources to the research, development, marketing and sales of their products, and adopt more aggressive pricing policies
F-3
PRE
Prenetics Global Limited - Ordinary Shares
17 Jan 24
Shelf registration (foreign)
6:59am
track record in research and development, transforming technologies into commercial products and healthcare services that appeal to customers … to the research, development, marketing and sales of their products, and adopt more aggressive pricing policies than we do. As a result, our competitors may
6-K
EX-99.1
PRE
Prenetics Global Limited - Ordinary Shares
20 Nov 23
Prenetics Announces Third Quarter 2023 Financial Results
6:30am
net gain/(losses)
Selling and distribution expenses4
Research and development expenses4
Restructuring costs5
Administrative and other operating … and distribution expenses4
Research and development expenses4
Restructuring costs5
Administrative and other operating expenses4
Loss from operations
Fair
424B3
PRE
Prenetics Global Limited - Ordinary Shares
2 Nov 23
Prospectus supplement
4:04pm
of scientists, entrepreneurs and professionals, we believe that we have a strong capability and a proven track record in research and development … in customer requirements and emerging technologies, devote greater resources to the research, development, marketing and sales of their products
POS AM
6l2ri
6 Oct 23
Prospectus update (post-effective amendment)
1:52pm
F-3
35b903u
29 Sep 23
Shelf registration (foreign)
9:17am
6-K
EX-99.1
8xo0f3c0 2pkamd
18 Sep 23
Prenetics Announces Second Quarter 2023 Financial Results
9:09am
424B3
nfryzsc2q cdx
21 Jul 23
Prospectus supplement
6:16am
POS AM
7jy1kr gg9
6 Jul 23
Prospectus update (post-effective amendment)
9:00am
6-K
EX-99.1
q05cu
5 Jun 23
Prenetics Announces First Quarter 2023 Financial Results
7:18am
POS AM
vaopl 58em1wcf8r6
31 May 23
Prospectus update (post-effective amendment)
8:25am
POS AM
db0mzhx
1 May 23
Prospectus update (post-effective amendment)
5:19pm
6-K/A
EX-99.1
9ishv7 kvcp
1 May 23
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
4:03pm
POS AM
9scmwr6j0eby8 4jt8na
14 Dec 22
Prospectus update (post-effective amendment)
8:04am
6-K
EX-99.1
lshy cg9u3pjvtde
10 Nov 22
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
4:04pm
6-K
EX-99.1
inoct04 kgb359xr
9 Sep 22
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
4:32pm
424B3
g6rjiw
1 Jul 22
Prospectus supplement
4:10pm
F-1/A
uf70cr7 7e9nnpu
28 Jun 22
Registration statement (foreign) (amended)
4:02pm